echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The world's first declared clinical BTK-PROTAC ...

    The world's first declared clinical BTK-PROTAC ...

    • Last Update: 2021-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Source: Pharmaceutical Rubik's Cube Pro January 26, Hesco Pharmaceutical Group Co., Ltd. disclosed that its wholly-owned subsidiary Sichuan Haisco Pharmaceutical Co., Ltd. recently received the State Drug Administration issued a "notice of acceptance", its declared HSK29116 bulk drug clinical trial application was accepted by the State Drug Administration.
    HSK29116 is an oral PROTAC small molecule anti-tumor drug that selectively blocks BTK kinase activity and interferes with B cell development by regulating signaling path paths to control the progression of various B-cell malignancies.
    HSK29116 on the one hand can directly inhibit BTK activity by specific binding BTK, on the other hand, can induce BTK ubibination markers, through protease pathway degradation, thereby blocking the transmission of BCR signaling pathway, inhibit the growth and proliferation of B cell lymphoma cells, play a dual anti-tumor effect.
    At present, BTK small molecule inhibitors have been successfully applied to the treatment of B-cell lymphoma, but the existing listed BTK inhibitors are mainly through the formation of co-priced bonds with the cysteine residue of BTK active points to produce enzyme inhibition, side effects are large, co-price binding easy to produce drug-resistant mutations, become a major problem in clinical treatment.
    , HSK29116 not only has a better effect on wild BTK, but also overcomes drug-resistant mutations.
    if successful, it could lead to more clinical benefits and better treatments for patients with B-cell malignancies.
    HSK29116 is the world's first declared clinical oral BTK-PROTAC small molecule anti-tumor drug based on Hesco's PROTAC research and development platform.
    , there are no products with the same mechanism at home and abroad into clinical trials, is expected to become first-in-class drugs.
    PROTAC has been a hot topic in pharmaceutical research and development in recent years, known as Proteolysis-Targeting Chimeras, a protein hydrolysis-targeted chimeras that looks like dumbbells, connecting "interest protein ligands" through a "linker" and "recruiting ligands for E3 ubibin connective enzymes."
    , one end of the PROTACs molecule binds to the interest protein (i.e. the target protein) and the other end binds to the E3 ubigan connective enzyme.
    and E3 Ubibusin connective enzyme can mark a small protein called ubibin as defective or damaged by attaching it to the target protein.
    , the cell's protein crusher (i.e., protease) degrades the labeled target protein.
    protein degradation agents based on PROTAC have a unique advantage over conventional protein inhibitors.
    one of the biggest advantages of this is the ability to change the target from "undruggable" to "drug-free".
    most small molecule drugs or monoants need to bind to the active bits of enzymes or receptors to function, however, it is estimated that 80% of proteins in human cells lack such spots.
    and PROTAC only needs to bind to the target protein to specifically "mark" it.
    , PROTAC is also expected to address the resistance of traditional protein inhibitors.
    For example, in 2018, a paper published in Cell Research by Professor Raoof Tsinghua University confirmed that in-body experiments have shown that BTK protein degradation agents can target BTK proteins that degrade C481S mutations and overcome the resistance of B-cell malignancies to the clinical first-line drug erotinib, the world's first approved BTK inhibitor.
    2019, the team published the results of an in vivo experiment in the journal Leukemia, which showed that using PROTAC technology to degrade multiple mutant BTK proteins could overcome non-Hodgkin lymphomas that are resistant to erutinib.
    Arvinas, founded by PROTAC pioneer Professor Craig Crews, is one of the leading companies in the field, with two small molecules, PROTAC, currently conducting clinical trials targeting AR and ER, respectively, and has previously published positive clinical data.
    addition to Arvinas, start-ups such as C4 Therapeutics and Kymera Therapeutics are also competing.
    is in agreement with the start-up's rush to launch a new generation of small-molecule drugs around PROTAC technology, with pharmaceutical giants such as Roche, Pfizer, Bayer, Biogen, Mercedon, GSK, Novarma and AstraZenece also setting up PROTACs.
    Domestic, in addition to Haisco, to open up the pharmaceutical industry, and path medicine, No cheng Jianhua, five yuan biology, Meizhi Pharmaceuticals, Yasheng Pharmaceuticals, Colum Pharmaceuticals, Hengrui, Shi Pharmaceutical Group, Jiaxing Uber, Haicheng Pharmaceuticals, Xingxuan original organisms, Shanghai Ruiin, Didi Technology, Lintai Biologicals, multi-domain biology, tongyuan Kang and other companies have been laid out.
    's IND declaration or will start the domestic PROTAC drug clinical research and development journey, so fierce competition, the future who is the main float, the next two or three years is very critical.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.